Literature DB >> 1705412

Illimaquinone, a selective inhibitor of the RNase H activity of human immunodeficiency virus type 1 reverse transcriptase.

S Loya1, R Tal, Y Kashman, A Hizi.   

Abstract

We studied the effect of the natural marine substance illimaquinone on the catalytic activities of reverse transcriptase from human immunodeficiency virus type 1. Illimaquinone inhibited the RNase H activity of the enzyme at concentrations of 5 to 10 microgram/ml, whereas RNA-dependent DNA polymerase and DNA-dependent DNA polymerase activities were considerably less susceptible to this inhibition. Two synthetic derivatives of illimaquinone, in which the 6'-hydroxyl group at the ortho position to one of carbonyl groups of the quinone ring was modified, proved ineffective in inhibiting the human immunodeficiency virus type 1 reverse transcriptase RNase H function, suggesting involvement of the 6'-hydroxyl group in blocking the enzymatic activity.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1705412      PMCID: PMC171980          DOI: 10.1128/AAC.34.10.2009

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  27 in total

1.  Differential extension of 3' mispairs is a major contribution to the high fidelity of calf thymus DNA polymerase-alpha.

Authors:  F W Perrino; L A Loeb
Journal:  J Biol Chem       Date:  1989-02-15       Impact factor: 5.157

2.  Biosynthesis and analysis of a genetically engineered HIV-1 reverse transcriptase/endonuclease polyprotein in Escherichia coli.

Authors:  A Leuthardt; S F Le Grice
Journal:  Gene       Date:  1988-08-15       Impact factor: 3.688

3.  Human immunodeficiency virus reverse transcriptase-associated RNase H activity.

Authors:  M C Starnes; Y C Cheng
Journal:  J Biol Chem       Date:  1989-04-25       Impact factor: 5.157

4.  Comparison of inhibitory activities of various antiretroviral agents against particle-derived and recombinant human immunodeficiency virus type 1 reverse transcriptases.

Authors:  R F Schinazi; B F Eriksson; S H Hughes
Journal:  Antimicrob Agents Chemother       Date:  1989-01       Impact factor: 5.191

5.  Antimoniotungstate (HPA 23) treatment of three patients with AIDS and one with prodrome.

Authors:  W Rozenbaum; D Dormont; B Spire; E Vilmer; M Gentilini; C Griscelli; L Montagnier; F Barre-Sinoussi; J C Chermann
Journal:  Lancet       Date:  1985-02-23       Impact factor: 79.321

6.  RNA-dependent DNA polymerase of avian sarcoma virus B77. I. Isolation and partial characterization of the alpha, beta2, and alphabeta forms of the enzyme.

Authors:  A Hizi; W K Joklik
Journal:  J Biol Chem       Date:  1977-04-10       Impact factor: 5.157

7.  Substrate binding in human immunodeficiency virus reverse transcriptase. An analysis of pyridoxal 5'-phosphate sensitivity and identification of lysine 263 in the substrate-binding domain.

Authors:  A Basu; R S Tirumalai; M J Modak
Journal:  J Biol Chem       Date:  1989-05-25       Impact factor: 5.157

8.  Ribonuclease H activities associated with viral reverse transcriptases are endonucleases.

Authors:  M S Krug; S L Berger
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

9.  Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides.

Authors:  H Mitsuya; S Broder
Journal:  Proc Natl Acad Sci U S A       Date:  1986-03       Impact factor: 11.205

10.  Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex.

Authors:  R Yarchoan; R W Klecker; K J Weinhold; P D Markham; H K Lyerly; D T Durack; E Gelmann; S N Lehrman; R M Blum; D W Barry
Journal:  Lancet       Date:  1986-03-15       Impact factor: 79.321

View more
  18 in total

Review 1.  Antiviral therapy for human immunodeficiency virus infections.

Authors:  E De Clercq
Journal:  Clin Microbiol Rev       Date:  1995-04       Impact factor: 26.132

Review 2.  Targeting Metalloenzymes for Therapeutic Intervention.

Authors:  Allie Y Chen; Rebecca N Adamek; Benjamin L Dick; Cy V Credille; Christine N Morrison; Seth M Cohen
Journal:  Chem Rev       Date:  2018-09-07       Impact factor: 60.622

3.  Subunit-specific mutagenesis of the cysteine 280 residue of the reverse transcriptase of human immunodeficiency virus type 1: effects on sensitivity to a specific inhibitor of the RNase H activity.

Authors:  S Loya; H Q Gao; O Avidan; P L Boyer; S H Hughes; A Hizi
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

4.  Polycitone A, a novel and potent general inhibitor of retroviral reverse transcriptases and cellular DNA polymerases.

Authors:  S Loya; A Rudi; Y Kashman; A Hizi
Journal:  Biochem J       Date:  1999-11-15       Impact factor: 3.857

5.  Mode of inhibition of HIV reverse transcriptase by 2-hexaprenylhydroquinone, a novel general inhibitor of RNA-and DNA-directed DNA polymerases.

Authors:  S Loya; A Rudi; Y Kashman; A Hizi
Journal:  Biochem J       Date:  1997-06-15       Impact factor: 3.857

6.  Positional adaptability in the design of mutation-resistant nonnucleoside HIV-1 reverse transcriptase inhibitors: a supramolecular perspective.

Authors:  Aldo Bruccoleri
Journal:  AIDS Res Hum Retroviruses       Date:  2012-10-04       Impact factor: 2.205

7.  Identification of alternative binding sites for inhibitors of HIV-1 ribonuclease H through comparative analysis of virtual enrichment studies.

Authors:  Anthony K Felts; Krystal Labarge; Joseph D Bauman; Dishaben V Patel; Daniel M Himmel; Eddy Arnold; Michael A Parniak; Ronald M Levy
Journal:  J Chem Inf Model       Date:  2011-07-26       Impact factor: 4.956

8.  Specific inhibition of the reverse transcriptase of human immunodeficiency virus type 1 and the chimeric enzymes of human immunodeficiency virus type 1 and type 2 by nonnucleoside inhibitors.

Authors:  A Hizi; R Tal; M Shaharabany; M J Currens; M R Boyd; S H Hughes; J B McMahon
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191

9.  RNase H activity associated with reverse transcriptase from feline immunodeficiency virus.

Authors:  R C Cronn; J D Whitmer; T W North
Journal:  J Virol       Date:  1992-02       Impact factor: 5.103

Review 10.  Reactivity and biological activity of the marine sesquiterpene hydroquinone avarol and related compounds from sponges of the order Dictyoceratida.

Authors:  Dusan Sladić; Miroslav J Gasić
Journal:  Molecules       Date:  2006-01-31       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.